Lex Diagnostics began commercial rollout of Velo, a point‑of‑care qPCR platform that secured FDA 510(k) clearance and a CLIA waiver for a flu/COVID cartridge. Velo performs true sample‑to‑answer, cartridge‑based qPCR in roughly 10 minutes using thin flat reaction chambers and rapid heating chemistry to achieve ultra‑fast cycles without higher reagent concentrations. The platform targets clinics and decentralized labs by offering rapid, low‑cost cartridges and claims scalable manufacturing. Lex positions Velo against other ultra‑fast POC systems by touting a 10‑minute turnaround and inexpensive, automatable cartridges. If adoption scales, Velo could shift diagnostic algorithms for respiratory pathogens by enabling actionable molecular results during patient visits, but commercial success will hinge on reimbursement, supply‑chain scale and real‑world performance.